Autolus Therapeutics plc (AUTL) and Concert Pharmaceuticals Inc. (NASDAQ:CNCE) Comparing side by side

Autolus Therapeutics plc (NASDAQ:AUTL) and Concert Pharmaceuticals Inc. (NASDAQ:CNCE) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Autolus Therapeutics plc 13 0.00 33.90M -1.40 0.00
Concert Pharmaceuticals Inc. 7 0.00 19.14M -3.13 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Autolus Therapeutics plc and Concert Pharmaceuticals Inc.

Profitability

Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Autolus Therapeutics plc 262,180,974.48% 0% 0%
Concert Pharmaceuticals Inc. 287,819,548.87% -41.7% -36.5%

Analyst Ratings

Ratings and Recommendations for Autolus Therapeutics plc and Concert Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Autolus Therapeutics plc 0 0 1 3.00
Concert Pharmaceuticals Inc. 0 0 3 3.00

Autolus Therapeutics plc’s upside potential is 63.32% at a $26 consensus price target. Competitively Concert Pharmaceuticals Inc. has an average price target of $21, with potential upside of 175.95%. The results from earlier shows that analysts opinion suggest that Concert Pharmaceuticals Inc. seems more appealing than Autolus Therapeutics plc.

Institutional and Insider Ownership

Autolus Therapeutics plc and Concert Pharmaceuticals Inc. has shares held by institutional investors as follows: 45.07% and 81.8%. Autolus Therapeutics plc’s share held by insiders are 3.52%. Comparatively, 3.2% are Concert Pharmaceuticals Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Autolus Therapeutics plc 17.44% -6.66% -44.05% -41.72% -34.88% -53.05%
Concert Pharmaceuticals Inc. -4.55% -16.72% -1.28% -29.5% -38.24% -19.84%

For the past year Concert Pharmaceuticals Inc. has weaker performance than Autolus Therapeutics plc

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. The companyÂ’s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with AlzheimerÂ’s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis. It product candidates that have completed Phase 1 clinical trials comprise CTP-730 for use in the treatment of inflammation or cancer; JZP-386 for use in the treatment of excessive daytime sleepiness and cataplexy; and CTP-543 for use in the treatment of alopecia areata. The company has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.